Matrixx Investor Battle Could Spur Overdisclosure

Law360, New York (October 5, 2010, 4:12 PM EDT) -- The U.S. Supreme Court fight between Matrixx Initiatives Inc. and investors over whether the Zicam cold remedy maker should have revealed adverse event reports could change disclosure standards for consumer product makers and inundate shareholders with information, attorneys say.

While Matrixx asked the high court to address shareholder disclosure requirements that are specific to pharmaceutical companies, the appeals court decision could spark overdisclosure in a host of other consumer-product industries, according to Anne E. Cohen of Debevoise & Plimpton LLP.

"For automobiles, for consumer products generally...
To view the full article, register now.